Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¹æ±¤ÀÌÇà»óÇǼ¼Æ÷¾Ï¿¡¼­ p53À¯ÀüÀÚÀÇ º¯È­ Altered Expressions and Point Mutations of p53 in Human Bladder Transitional Cell Carcinomas

´ëÇѺñ´¢±â°úÇÐȸÁö 1997³â 38±Ç 8È£ p.814 ~ 822
¼Ò¼Ó »ó¼¼Á¤º¸
±è¹ý¿Ï/Bup Wan Kim ±ÇűÕ/³ë±â¼®/Á¤¼º±¤/Àå¼¼±¹/Á¤¿îº¹/±èÁ¤¿Ï/Tae Gyun Kwon/Ki Suck Noh/Sung Kwang Chung/Sae Kook Chang/Woon Bok Chung/Jung Wan Kim

Abstract

°á·Ð
25·ÊÀÇ ¹æ±¤ÀÌÇà»óÇǼ¼Æ÷¾Ï ȯÀÚ¸¦ ´ë»óÀ¸·Î IHC¸¦ ½Ç½ÃÇÏ¿© ¹æ±¤¾ÏÀÇ ¾Ç¼ºµµ¿¡ µû¸¥
p53 ´Ü¹éÀÇ °ú¹ßÇöÀ» Á¶»çÇÏ°í p53 À¯ÀüÀÚÀÇ conserved exon(exon 5-8)¿¡ ´ëÇÑ PCR-SSCP
ºÐ¼®°ú ¿°±â¼­¿­ºÐ¼®À» ½Ç½ÃÇÏ¿© µ¹¿¬º¯À̸¦ Á¶»çÇÏ¿´´Ù.
IHC °á°ú 20·ÊÁß 15·Ê(75%)¿¡¼­ p53 ´Ü¹éÀÇ °ú¹ßÇöÀÌ °üÂûµÇ¾ú°í Á¾¾çÀÇ ¾Ç¼ºµµ°¡ Áõ°¡
ÇÒ¼ö·Ï p53´Ü¹éÀÇ ¹ßÇöµµ °­ÇÏ°Ô ³ªÅ¸³ª p53 ´Ü¹éÀÇ ¹ßÇö°­µµ¿Í ¾Ç¼ºµµ »çÀÌ¿¡ »ó°ü¼ºÀÌ
ÀÖÀ½À» ¾Ë ¼ö ÀÖ¾ú´Ù.
PCR-SSCP¿¡¼­´Â 25¸íÁß 10¸í (40%)¿¡¼­ 13·ÊÀÇ ÀÌ»ó band À̵¿ÀÌ °üÂûµÇ¾ú°í ÀÌÁß 8
·Ê (62%)°¡ exon 8¿¡¼­ band À̵¿¿¡ ÀÌ»óÀÌ ¹ß°ßµÇ¾î ÀÌ ºÎÀ§¿¡¼­ µ¹¿¬º¯ÀÌ°¡ °¡Àå ºó¹ßÇÏ
´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù.
¿°±â¼­¿­ºÐ¼® °á°ú PCR-SSCP»ó¿¡¼­ band À̵¿¿¡ ÀÌ»óÀ» º¸ÀÎ ½Ã·á ¸ðµÎ¿¡¼­ Çٻ꿰±â
ÀÇ º¯È­°¡ È®ÀεǾú´Âµ¥ ¸ðµÎ°¡ Á¡µ¹¿¬º¯ÀÌ¿´°í ±× Áß 10·Ê°¡ G:C¡æA:T transitionÀ̾ú´Ù.
À¯ÀüÀÚº¯ÀÌ°¡ ÀϾ 10·ÊÁß 3·Ê´Â codon 285¿¡¼­ GAG (Glu)°¡ AAG (Lys)À¸·Î, 2·Ê´Â
codon 280¿¡¼­ AGA(Arg)°¡ AAA (Lys)À¸·Î º¯°æµÇ¾î ÀÌ ºÎÀ§°¡ hot spotÀ¸·Î ³ªÅ¸³µ´Ù.
µÎ °Ë»çÀÇ º´ÇàÀ» ÅëÇÑ ¹æ±¤ÀÌÇà»óÇÇ ¼¼Æ÷¾ÏÀÇ È®ÀÎÀ²À» º¸¸é 20¸íÁß 17¸í (80.5%)¿¡¼­
ÃÖ¼ÒÇÑÇÑ °Ë»ç¿¡¼­ ¾ç¼ºÀ» º¸¿´´Âµ¥ grade ¥±¿¡¼­´Â 4·Ê Áß 2·Ê, grade ¥²¿¡¼­´Â 9·Ê Áß 8
·Ê, grade ¥³¿¡¼­´Â Á¶»çÇÑ 7¸í ¸ðµÎ°¡ ¾ç¼ºÀ» º¸¿© grade°¡ ³ôÀ»¼ö·Ï µÎ °Ë»çÁß Çϳª¿¡¼­
¾ç¼ºÀ» º¸ÀÏ È®·üÀÌ ³ô°Ô ³ªÅ¸³µ´Ù.
ÀÌ»óÀÇ °á°ú·Î ¹æ±¤¾ÏȯÀÚ¿¡¼­ ¸é¿ªÁ¶Á÷È­ÇÐ °Ë»ç¿Í ºÐÀÚ»ý¹°ÇÐÀû ¹æ¹ý(PCR-SSCP, ¿°±â
¼­¿­ ºÐ¼® µî)À» ÇÔ²² ½ÃÇàÇÒ °æ¿ì Á¾¾çÀÇ Áø´Ü ¹× ¿¹ÈÄÆÇÁ¤¿¡ µµ¿òÀÌ µÇ¸®¶ó »ý°¢µÈ´Ù.
#ÃÊ·Ï#
The objective of this study was to characterise the pattern of p53 mutations in
bladder tumor. In this study, 25 bladder transitional cell carcinomas were analyzed by
immunohistochemistry (IHC) for p53 nuclear overexpression, and the results were
compared with those of polymerase chain reaction-single strand conformational
polymorphism (PCR-SSCP) analysis in exon 5-8 of the p53 gene and DNA sequencing
analysis. 15 out of 20 cases (75%) showed p53 nuclear immunoreactivities on IHC. On
PCR-SSCP analysis, 10 out of 25 cases (40%) had abnormal shifts in mobility. 62% of
the mutations were in exon 8. Direct DNA sequencing analysis were performed in these
10 cases to confirm the presence of mutated p53 genes and to determine the type of
mutations. Sixteen point mutations were detected in 10 cases. Two specimens had
double mutations and another two had triple mutations. G:C¡æA:T transitions were the
most frequent patterns (62.5%). One mutation was a premature stop codon and two
were silent mutations. Three out of 10 had a point mutation at codon 285 (GAG/Glu¡æ
AAG/Lys) and two had at codon 280 (AGA/Arg¡æAAA/Lys). One of 16 mutations was
transition at hot spot codon 273 with CpG site.
These results suggest that altered expressions and point mutations of p53 occured in
all grade of bladder cancer, but are more associated with high grade bladder tumors. To
elucidate the carcinogenesis of bladder cancer, further studies should be carried out.

Å°¿öµå

Bladder tumor; p53; Immunohisochemistry; PCR-SSCP analysis;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS